Brittany C. Morreale

Brittany Morreale is an associate in Goodwin’s nationally recognized Life Sciences group. Brittany advises companies throughout the full range of the corporate life cycle, and has worked with many of her company-side clients since their initial founding and funding.

Brittany represents public and private companies in startup and formation matters, venture capital financings, mergers and acquisitions, initial public offerings and capital markets transactions, strategic investments, and other complex transactions. She also represents publicly traded biotechnology companies in ongoing corporate matters, including SEC compliance and corporate governance matters. She joined Goodwin in 2018.

Brittany’s recent client representations include the following:

• Ansys in its acquisition of Helic
• eGenesis in its $100 million Series B financing, $125 million Series C financing and $191 million Series D financing
• Thrive Earlier Detection in its $110 million Series A financing, $257 million Series B financing and sale to Exact Sciences for up to $2.15 billion
• Nimbus Therapeutics in its financings of more than $165 million
• Entrada Therapeutics in its $25 million Series A financing extension, $116 million Series B financing, $181.5 million upsized initial public offering, $100 million registered direct offering, and collaboration with Vertex Pharmaceuticals for $250 million in equity and upfront payments, up to $485 million in milestone payments, and royalties
• iTeos Therapeutics in its $201 million initial public offering
• Cowen and Company in Albireo Pharma’s $150 million follow-on offering
• ARTBIO in its $23 million Series Seed financing and $90 million Series A financing
• Myeloid Therapeutics in its $73 million Series B financing 
• Flagship Pioneering in its partnership with Pfizer with $100 million combined commitment
• Flagship Pioneering in Novo Nordisk’s research collaboration with Metaphore Biotechnologies
• Flagship Pioneering in its partnership with GSK with initial funding up to $150 million
• Rosemont Pharmaceuticals in its acquisition of Sabal Therapeutics and its affiliates
• Abcuro in its $200 million Series C financing

Ms. Morreale is a member of the Boston Bar Association.

While attending law school, Brittany served as editor-in-chief of the Boston College Journal of Law & Social Justice, which consolidated with the Boston College Law Review in 2017. In 2017, Brittany was named the John D. Cooney Scholar for her contribution as an active and engaged member of the Boston College Law School community.